Skip to content

Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance

Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance in Patients With Desaturating Chronic Lung Disease: a Randomized Clinical Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05267418
Enrollment
30
Registered
2022-03-04
Start date
2019-02-26
Completion date
2021-03-30
Last updated
2022-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Dyspnea, Interstitial Lung Disease, Lung Diseases, Pulmonary Hypertension

Brief summary

The main purpose of this study is to evaluate the effects of automated oxygen administration (FreeO2 system) alone or with high-flow oxygen on dyspnea and exercise tolerance in people with desaturating chronic lung disease compared to fixed oxygen therapy.

Interventions

DEVICEAutomated nasal O2 titration with FreeO2

The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)

Sponsors

Laval University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Masking description

The participant was not inform about what kind of oxygen support was provided during exercise

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

One of them * Moderate to severe COPD (forced expiratory volume in 1 second (FEV1) \< 80% predicted and FEV1/forced vital capacity (FVC) ratio \< 0.7) * Chronic interstitial lung disease such as usual interstitial pneumonitis (UIP), non-specific interstitial pneumonitis (NSIP) or hypersensitivity pneumonitis on high-resolution computed tomography * Pulmonary arterial hypertension type 1 or 4, excluding involvement secondary to collagenosis as well as secondary to congenital heart disease, as diagnosed with mean pulmonary artery pressure \> 25 mm Hg at right heart catheterization * Cystic fibrosis, as diagnosed by a positive sweat test (\>60 mmol/L) or having 2 genetic mutations known to cause cystic fibrosis. AND having a 6-minute walking test with significant desaturation defined as a decrease in O2 saturation greater or equal to 5% with O2 saturation at the end of the walking test \< 88%

Exclusion criteria

* Exacerbation of the primary lung disease in the past 8 weeks * Exercise limiting diseases other than the primary lung disease. * Not reaching the target dyspnea score during the walking tests. * Stage 1 pulmonary sarcoidosis * History of syncope on exertion * SpO2 with effort less than 90% despite the use of 6 L of O2 per minute * Cardiac condition deemed unstable or severe (e.g. severe aortic stenosis) * Disabling or severe rheumatological or neurological condition * Participation in a pulmonary rehabilitation program within the last year * Patients with multi-resistant bacteria

Design outcomes

Primary

MeasureTime frameDescription
Dyspnea scoreAt the end of the 3 minute-constant speed shuttle test (CSST) (3 minutes), immediately after the intervention (either fixed-O2, automated nasal O2 adjustment alone, or automated nasal O2 adjustment + high nasal flow)Dyspnea score on the modified Borg scale (0 to 10, with higher score indicating worse dyspnea)

Secondary

MeasureTime frameDescription
Endurance time duration of the Endurance Shuttle Walking Test (EWST)Duration in (mm:ss) of Endurance Shuttle Walking Test (ESWT), immediately after the intervention (either fixed-O2, automated nasal O2 adjustment alone, or automated nasal O2 adjustment + high nasal flow)Total duration of Endurance Shuttle Walking Test
Mean pulsed O2 saturation (SpO2) during Endurance Shuttle Walking Test (EWST)From the beginning to the end of the Endurance Shuttle Walking Test (ESWT) which will be done on 3 testing days, with either fixed O2, automatic O2 adjustment alone, or automatic O2 adjustment + high nasal flowMean % pulsed O2 saturation (SpO2) during the Endurance Shuttle Walking Test (ESWT)

Other

MeasureTime frameDescription
Mean pulsed O2 saturation (SpO2) during 3min-CSSTFrom the beginning to the end of the 3 minute-constant speed shuttle test which will be done on 3 testing days with either fixed O2, automatic O2 adjustment alone, or automatic O2 adjustment + high nasal flow)The mean % pulsed O2 saturation (SpO2) during the test duration time
Capillary blood gasesDifference the baseline capillary PCO2 from the resting values (before Endurance Shuttle Walking Test - ESWT) to the end of exercise values (after the Endurance Shuttle Walking Test - ESWT) immediately after the interventionCarbon dioxide partial pressure (PCO2), lactate

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026